Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction

This publication has 38 references indexed in Scilit:

• Reduction in infarct size by the prostacyclin analogue iloprost (ZK 36374) after experimental coronary artery occlusion-reperfusion
  American Heart Journal, 1988
• Beneficial effects of iloprost in the stunned canine myocardium.
  Circulation Research, 1988
• Iloprost inhibits neutrophil function in vitro and in vivo and limits experimental infarct size in canine heart.
  Circulation Research, 1987
• Early and late administration of a PGI2-analogue, ZK 36 374 (iloprost): effects on myocardial preservation, collateral blood flow and infarct size
  Cardiovascular Research, 1984
• Inhibition of Oxygen-Centered Free Radical Formation by the Stable Prostacyclin-Mimetic Iloprost (ZK 36 374) in Acute Myocardial Ischemia
  Journal of Cardiovascular Pharmacology, 1984
• Salvage of ischemic myocardium by prostacyclin during experimental myocardial infarction
  Journal of the American College of Cardiology, 1983
• Prostaglandin E1 and prostaglandin I2 modulation of superoxide production by human neutrophils
  Biochemical and Biophysical Research Communications, 1983
• Dissimilar effects of prostacyclin, prostaglandin E1, and prostaglandin E2 on myocardial infarct size after coronary occlusion in conscious dogs.
  Circulation Research, 1981
• Prostacyclin in experimental myocardial ischemia: Effects on hemodynamics, regional myocardial blood flow, infarct size and mortality
  The American Journal of Cardiology, 1981
• Prostacyclin: A Potentially Valuable Agent for Preserving Myocardial Tissue in Acute Myocardial Ischemia
  Science, 1978